Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Pipeline Review, H2 2017’, provides in depth analysis on Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Hormonal Disorders, Oncology, Metabolic Disorders, Central Nervous System, Gastrointestinal, Genetic Disorders and Ophthalmology under development targeting Somatostatin Receptor Type 2 (SRIF1 or SSTR2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 2 (SRIF1 or SSTR2)

The report reviews Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics and enlists all their major and minor projects

The report assesses Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 2 (SRIF1 or SSTR2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 2 (SRIF1 or SSTR2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Amryt Pharma plc

Crinetics Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Ipsen SA

Progenics Pharmaceuticals Inc

Strongbridge Biopharma plc

Zucara Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Overview

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Companies Involved in Therapeutics Development

Amryt Pharma plc

Crinetics Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Ipsen SA

Progenics Pharmaceuticals Inc

Strongbridge Biopharma plc

Zucara Therapeutics Inc

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Drug Profiles

AP-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CRN-00808 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Edotreotide Labeled Yttrium 90 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lanreotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lanreotide SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRL-2903 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize SSTR2 for Neuroendocrine Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Antagonize Somatostatin Receptor Type 2 for Neuroendocrine Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veldoreotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Dormant Products

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Discontinued Products

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Product Development Milestones

Featured News & Press Releases

Sep 21, 2017: JDRF Funds Zucara Therapeutics Approach to Preventing Hypoglycemia in People with Type 1 Diabetes

Sep 18, 2017: U.S. FDA Approves New Indication for Ipsen’s Somatuline Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome

Sep 04, 2017: Ipsen To Present Data on Somatuline at European Society of Medical Oncology congress

Jul 13, 2017: Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808

Jul 03, 2017: Somatuline Autogel 120 mg receives Japanese approval for a new indication for the treatment of gastro-entero-pancreatic neuroendocrine tumors

Jun 01, 2017: Ipsen To Present New Data of Lanreotide at ASCO

Mar 09, 2017: Ipsen announces data presentation on lanreotide (Somatuline Autogel) at the European Neuroendocrine Tumor Society (ENETS) 2017 conference

Feb 06, 2017: Amryt Pharma Announces positive pre-clinical study results for drug compound with potential to treat acromegaly, AP102

Dec 02, 2016: Amryt Pharma provides update on AP-102

Nov 07, 2016: FDA Orphan Drug Designation Received for Drug Compound with Potential to Treat Acromegaly

Sep 30, 2016: Ipsen Biopharmaceuticals Announces Nine Poster Presentations at the 2016 North American Neuroendocrine Tumor Society Symposium

Sep 27, 2016: Ipsen Announces Data Presentations of Lanreotide (Somatuline Autogel) at the European Society for Medical Oncology (ESMO) 2016 Congress

Jul 27, 2016: Supplemental Application Filed for Somatuline in Japan for Additional Indication of Neuroendocrine Tumors

Jun 04, 2016: Endocrine Practice Publishes ELECT Phase III Trial Results in Adults with Carcinoid Syndrome

Jun 02, 2016: Ipsen Announces Data Presentations of Somatuline Depot (lanreotide) Injection in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Amryt Pharma plc, H2 2017

Pipeline by Crinetics Pharmaceuticals Inc, H2 2017

Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017

Pipeline by Ipsen SA, H2 2017

Pipeline by Progenics Pharmaceuticals Inc, H2 2017

Pipeline by Strongbridge Biopharma plc, H2 2017

Pipeline by Zucara Therapeutics Inc, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports